GROWTH HORMONE / PEPTIDE CARD

Ipamorelin

A synthetic ghrelin-receptor agonist studied as a growth hormone secretagogue, without an FDA-approved therapeutic product.

PEPTIDE CARDIpamorelin

Reviewed
August 7, 2026

Human evidence

2/5 · Early human research

U.S. FDANot FDA approved

2026 WADAProhibited

Inspect 2 sources

On this page

WHAT THE EVIDENCE SAYS

Ipamorelin evidence summary.

Ipamorelin has human exposure data, but the evidence base is narrow and does not validate generalized anti-aging or body-composition claims.

Entity type
Synthetic peptideSource snapshot
August 7, 2026Record status
Sources attached

Do not overread this record

Secretagogue activity is a mechanism, not proof of a desirable long-term health outcome.

01 / CLASSIFICATION

What is Ipamorelin?

Entity typeSynthetic peptide

Research categoryGrowth Hormone

Known namesIpamorelin

Editorial unitOne molecule or defined product record

Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.

Class: Growth-hormone-axis peptides Goal: Growth Hormone Axis

02 / EVIDENCE

Ipamorelin human and preclinical evidence.

HUMAN

2/5 · Early human research

Limited pharmacology and postoperative-ileus research does not establish broad therapeutic use.

PRECLINICAL

3/5 · Mechanism established

Growth-hormone secretagogue activity is established; long-term clinical benefit and safety are not.

The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.

03 / STATUS

Ipamorelin FDA and sport status.

U.S. FDANo FDA-approved drug product; FDA identifies significant safety and characterization concerns for compounding.

2026 WADAProhibited at all times under the 2026 WADA List (S2).

Commercial accessPeptideAgent does not route unapproved research substances to sellers.

Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.

04 / RESEARCH AREAS

What is Ipamorelin being studied for?

01Growth hormone secretion

02Ghrelin receptor

03Postoperative ileus

04Endocrine pharmacology

05 / COMPARISONS

Compare Ipamorelin.

Tesamorelin vs IpamorelinAn approved GHRH analog compared with an unapproved ghrelin-receptor agonist.CJC-1295 vs IpamorelinEarly endocrine research compared without treating biomarker changes as outcomes.Ipamorelin vs SermorelinTwo unapproved growth-hormone-axis peptides with different mechanisms and evidence histories.

06 / LATEST & DEFINING SOURCES

Ipamorelin primary and official sources.

FDA / 2024–2026FDA briefing and compounding safety concerns for ipamorelin

U.S. FDA

WADA / 20262026 Prohibited List

World Anti-Doping Agency

07 / QUESTIONS

Questions about Ipamorelin.

Start with identity, research, human evidence, approval, sport status, and the limits of the current record.

EvidenceWhat is the evidence for Ipamorelin?

Ipamorelin has human exposure data, but the evidence base is narrow and does not validate generalized anti-aging or body-composition claims.

ResearchWhat is Ipamorelin being studied for?

Current source-backed research areas include Growth hormone secretion, Ghrelin receptor, Postoperative ileus, Endocrine pharmacology. These areas describe investigation, not established personal benefit.

FDA statusIs Ipamorelin FDA approved?

Current U.S. status for Ipamorelin: No FDA-approved drug product; FDA identifies significant safety and characterization concerns for compounding.

Sport statusIs Ipamorelin prohibited in sport?

Current sport-status snapshot for Ipamorelin: Prohibited at all times under the 2026 WADA List (S2).

Evidence limitsWhat are the main evidence limits for Ipamorelin?

Secretagogue activity is a mechanism, not proof of a desirable long-term health outcome.